Skip to Content

Erwinaze (asparaginase erwinia chrysanthemi) Disease Interactions

There are 3 disease interactions with Erwinaze (asparaginase erwinia chrysanthemi):

Major

Asparaginase Erwinia chrysanthemi (Includes Erwinaze) ↔ pancreatitis

Severe Potential Hazard, Moderate plausibility. Applies to: Pancreatitis

The use of asparaginase Erwinia chrysanthemi is contraindicated in patients with a history of serious pancreatitis with prior L-asparaginase therapy. It is recommended to evaluate patients with symptoms compatible with pancreatitis to establish a diagnosis. In the case of mild pancreatitis, it is recommended to hold treatment until the signs and symptoms subside, and amylase levels return to normal. Discontinue treatment with this agent for severe or hemorrhagic pancreatitis manifested by abdominal pain >72 hours and amylase elevation of >= 2.0 x ULN.

Major

Asparaginase Erwinia chrysanthemi (Includes Erwinaze) ↔ thrombotic events

Severe Potential Hazard, Moderate plausibility. Applies to: Thrombotic/Thromboembolic Disorder, Bleeding

Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism have been reported with the use of Erwinia-derived L-asparaginase therapy. Its use is contraindicated in patients with history of serious thrombosis or hemorrhagic events with prior L-asparaginase therapy. It is recommended to exercise caution in patients predisposed to thrombotic or hemorrhagic events. It is recommended to discontinue asparaginase Erwinia chrysanthemi if thrombotic or hemorrhagic event occur until symptoms resolve.

Moderate

Asparaginase Erwinia chrysanthemi (Includes Erwinaze) ↔ diabetes

Moderate Potential Hazard, Moderate plausibility. Applies to: Diabetes Mellitus

The use of asparaginase Erwinia chrysanthemi has been associated with glucose intolerance. Exercise caution when using this agent in patients with diabetes. It is recommended to monitor glucose levels at the start of therapy, and periodically thereafter in all patients. Administer insulin therapy as necessary in patients with hyperglycemia.

Erwinaze (asparaginase erwinia chrysanthemi) drug interactions

There are 75 drug interactions with Erwinaze (asparaginase erwinia chrysanthemi)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide